Oncology drug costs overall, and immunotherapy costs specifically, drove Medicare spending increases for outpatient end-of-life cancer care, according to research in International Journal of Radiation Oncology, Biology, Physics.Expanding use of biosimilars may be an effective approach to moderate cancer drug costs, researchers concluded.